Matthew Yan's questions to HUTCHMED (China) Ltd (HCM) leadership • H1 2025
Question
Matthew Yan of CITIC CLSA asked about the ATTC platform, including the timing for target disclosure and the frontline development strategy. He also inquired about the reasons for the recent sales decline and the updated regulatory timeline for the SYK inhibitor, sofloplanib.
Answer
CEO Weiguo Su and EVP & Chief Medical Officer Michael Shi responded. Dr. Su stated that the target and preclinical data for the first ATTC candidate, A251, will be disclosed at the upcoming EORTC conference. The development strategy includes both monotherapy and combination approaches, with potential for rapid registration. He explained the sales decline was transitory, caused by compliance pressures and sales team changes, with a recovery already observed in Q2. Regarding the SYK inhibitor, the company is now focusing on a CMC-based solution for the impurity issue, targeting an NDA resubmission in H1 2026, and is exploring a new chemical entity for development outside of China.